Ossejtek alkalmazása a cardiovascularis betegségek kezelésében

Translated title of the contribution: Stem cell therapy in cardiovascular diseases

Márton Vértesaljai, Zsolt Piróth, Géza Fontos, György Andréka, Gusztáv Font, Gergely Szántho, Marienn Réti, T. Masszi, P. Andréka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Myocardial infarction is the leading cause of congestive heart failure in the industrialized world. Current treatments fail to address the underlying scarring and cell loss, which are the causes of ischaemic heart failure. Recent interest has focused on stem cells, which are undifferentiated and pluripotent cells that can proliferate, potentially self-renew, and differentiate into cardiomyocytes and endothelial cells. Myocardial regeneration is the most widely studied and debated example of stem cell plasticity. Early reports from animal and clinical investigations disagree on the extent of myocardial renewal in adults, but evidence indicates that cardiomyocytes were generated in what was previously considered a postmitotic organ. So far, candidates for cardiac stem cell therapy have been limited to patients with acute myocardial infarction and chronic ischaemic heart failure. Currently, bone marrow stem cells seem to be the most attractive cell type for these patients. The cells may be delivered by means of direct surgical injection, intracoronary infusion, retrograde venous infusion, and transendocardial infusion. Stem cells may directly increase cardiac contractility or passively limit infarct expansion and remodeling. Early phase I clinical studies indicate that stem cell transplantation is feasible and may have beneficial effects on ventricular remodeling after myocardial infarction. Future randomized clinical trials will establish the magnitude of benefit and the effect on mortality after stem cell therapy.

Original languageHungarian
Pages (from-to)2383-2388
Number of pages6
JournalOrvosi Hetilap
Volume146
Issue number47
Publication statusPublished - 2005

Fingerprint

Cell- and Tissue-Based Therapy
Cardiovascular Diseases
Stem Cells
Heart Failure
Myocardial Infarction
Cardiac Myocytes
Ventricular Remodeling
Stem Cell Transplantation
Bone Marrow Cells
Cicatrix
Regeneration
Randomized Controlled Trials
Endothelial Cells
Injections
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vértesaljai, M., Piróth, Z., Fontos, G., Andréka, G., Font, G., Szántho, G., ... Andréka, P. (2005). Ossejtek alkalmazása a cardiovascularis betegségek kezelésében. Orvosi Hetilap, 146(47), 2383-2388.

Ossejtek alkalmazása a cardiovascularis betegségek kezelésében. / Vértesaljai, Márton; Piróth, Zsolt; Fontos, Géza; Andréka, György; Font, Gusztáv; Szántho, Gergely; Réti, Marienn; Masszi, T.; Andréka, P.

In: Orvosi Hetilap, Vol. 146, No. 47, 2005, p. 2383-2388.

Research output: Contribution to journalArticle

Vértesaljai, M, Piróth, Z, Fontos, G, Andréka, G, Font, G, Szántho, G, Réti, M, Masszi, T & Andréka, P 2005, 'Ossejtek alkalmazása a cardiovascularis betegségek kezelésében', Orvosi Hetilap, vol. 146, no. 47, pp. 2383-2388.
Vértesaljai M, Piróth Z, Fontos G, Andréka G, Font G, Szántho G et al. Ossejtek alkalmazása a cardiovascularis betegségek kezelésében. Orvosi Hetilap. 2005;146(47):2383-2388.
Vértesaljai, Márton ; Piróth, Zsolt ; Fontos, Géza ; Andréka, György ; Font, Gusztáv ; Szántho, Gergely ; Réti, Marienn ; Masszi, T. ; Andréka, P. / Ossejtek alkalmazása a cardiovascularis betegségek kezelésében. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 47. pp. 2383-2388.
@article{3fb5c5b3821443cb8e8807a3414adaf4,
title = "Ossejtek alkalmaz{\'a}sa a cardiovascularis betegs{\'e}gek kezel{\'e}s{\'e}ben",
abstract = "Myocardial infarction is the leading cause of congestive heart failure in the industrialized world. Current treatments fail to address the underlying scarring and cell loss, which are the causes of ischaemic heart failure. Recent interest has focused on stem cells, which are undifferentiated and pluripotent cells that can proliferate, potentially self-renew, and differentiate into cardiomyocytes and endothelial cells. Myocardial regeneration is the most widely studied and debated example of stem cell plasticity. Early reports from animal and clinical investigations disagree on the extent of myocardial renewal in adults, but evidence indicates that cardiomyocytes were generated in what was previously considered a postmitotic organ. So far, candidates for cardiac stem cell therapy have been limited to patients with acute myocardial infarction and chronic ischaemic heart failure. Currently, bone marrow stem cells seem to be the most attractive cell type for these patients. The cells may be delivered by means of direct surgical injection, intracoronary infusion, retrograde venous infusion, and transendocardial infusion. Stem cells may directly increase cardiac contractility or passively limit infarct expansion and remodeling. Early phase I clinical studies indicate that stem cell transplantation is feasible and may have beneficial effects on ventricular remodeling after myocardial infarction. Future randomized clinical trials will establish the magnitude of benefit and the effect on mortality after stem cell therapy.",
keywords = "Myocardial infarction, Myocardial regeneration, Stem cell therapy",
author = "M{\'a}rton V{\'e}rtesaljai and Zsolt Pir{\'o}th and G{\'e}za Fontos and Gy{\"o}rgy Andr{\'e}ka and Guszt{\'a}v Font and Gergely Sz{\'a}ntho and Marienn R{\'e}ti and T. Masszi and P. Andr{\'e}ka",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "2383--2388",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "47",

}

TY - JOUR

T1 - Ossejtek alkalmazása a cardiovascularis betegségek kezelésében

AU - Vértesaljai, Márton

AU - Piróth, Zsolt

AU - Fontos, Géza

AU - Andréka, György

AU - Font, Gusztáv

AU - Szántho, Gergely

AU - Réti, Marienn

AU - Masszi, T.

AU - Andréka, P.

PY - 2005

Y1 - 2005

N2 - Myocardial infarction is the leading cause of congestive heart failure in the industrialized world. Current treatments fail to address the underlying scarring and cell loss, which are the causes of ischaemic heart failure. Recent interest has focused on stem cells, which are undifferentiated and pluripotent cells that can proliferate, potentially self-renew, and differentiate into cardiomyocytes and endothelial cells. Myocardial regeneration is the most widely studied and debated example of stem cell plasticity. Early reports from animal and clinical investigations disagree on the extent of myocardial renewal in adults, but evidence indicates that cardiomyocytes were generated in what was previously considered a postmitotic organ. So far, candidates for cardiac stem cell therapy have been limited to patients with acute myocardial infarction and chronic ischaemic heart failure. Currently, bone marrow stem cells seem to be the most attractive cell type for these patients. The cells may be delivered by means of direct surgical injection, intracoronary infusion, retrograde venous infusion, and transendocardial infusion. Stem cells may directly increase cardiac contractility or passively limit infarct expansion and remodeling. Early phase I clinical studies indicate that stem cell transplantation is feasible and may have beneficial effects on ventricular remodeling after myocardial infarction. Future randomized clinical trials will establish the magnitude of benefit and the effect on mortality after stem cell therapy.

AB - Myocardial infarction is the leading cause of congestive heart failure in the industrialized world. Current treatments fail to address the underlying scarring and cell loss, which are the causes of ischaemic heart failure. Recent interest has focused on stem cells, which are undifferentiated and pluripotent cells that can proliferate, potentially self-renew, and differentiate into cardiomyocytes and endothelial cells. Myocardial regeneration is the most widely studied and debated example of stem cell plasticity. Early reports from animal and clinical investigations disagree on the extent of myocardial renewal in adults, but evidence indicates that cardiomyocytes were generated in what was previously considered a postmitotic organ. So far, candidates for cardiac stem cell therapy have been limited to patients with acute myocardial infarction and chronic ischaemic heart failure. Currently, bone marrow stem cells seem to be the most attractive cell type for these patients. The cells may be delivered by means of direct surgical injection, intracoronary infusion, retrograde venous infusion, and transendocardial infusion. Stem cells may directly increase cardiac contractility or passively limit infarct expansion and remodeling. Early phase I clinical studies indicate that stem cell transplantation is feasible and may have beneficial effects on ventricular remodeling after myocardial infarction. Future randomized clinical trials will establish the magnitude of benefit and the effect on mortality after stem cell therapy.

KW - Myocardial infarction

KW - Myocardial regeneration

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=33644852560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644852560&partnerID=8YFLogxK

M3 - Article

C2 - 16398150

AN - SCOPUS:33644852560

VL - 146

SP - 2383

EP - 2388

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 47

ER -